TET-13 is a positive allosteric modulator of the GABAA receptor with an EC50 of 5.65 μM, which is more potent than Etomidate (EC50: 9.29 μM). It exhibits strong anesthetic effects in both mice and rats, with an ED50 of 0.48 mg/kg in mice and 0.69 mg/kg in rats.

TET-13 (1 mg/mL, 0-30 min) is rapidly metabolized in the plasma of SD rats, with a half-life (T 1/2) of 0.48 minutes.

TET-13 exhibits potent anesthetic effects in both mice and rats, with an ED50 of 0.48 mg/kg and 0.69 mg/kg respectively, through intravenous administration (mice: 1.2 mg/kg, rats: 1.725 mg/kg). It offers a quicker recovery than etomidate. In rats, TET-13 (1.38 mg/kg, intravenous) does not significantly inhibit serum corticosterone, found at a concentration of 970.12 nM. Continuous infusion of TET-13 at 22 mg/kg/h results in shorter recovery and ambulation times compared to etomidate after 0.5, 1, and 2 hours in rats.